Expression of Ca 2+-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1738-1743

  Hattori, Kotaro ^a   Tanaka, Haruko ^a   Wakabayashi, Chisato ^a   Yamamoto, Noriko ^a   Uchiyama, Hirofumi ^a   Teraishi, Toshiya ^a   Hori, Hiroaki ^a,b   Arima, Kunimasa ^c   Kunugi, Hiroshi ^a,b  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

BDNF; CAPS2; Postmortem brain; Schizophrenia; Stanley neuropathology consortium

Indexed keywords

CALCIUM ION DEPENDENT ACTIVATOR PROTEIN FOR SECRETION 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; RISPERIDONE; SECRETORY PROTEIN; TATA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BIPOLAR DISORDER; BLOOD SAMPLING; BRAIN LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; EXON; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA;

ADULT; AGED; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTOPSY; BRAIN; CALCIUM-BINDING PROTEINS; CEREBRAL CORTEX; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; MALE; MENTAL DISORDERS; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROTEIN ISOFORMS; RISPERIDONE; RNA; SCHIZOPHRENIA; TATA-BOX BINDING PROTEIN; TIME FACTORS; VESICULAR TRANSPORT PROTEINS;

EID: 79961128145     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.05.004     Document Type: Article

References (34)

1. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005, 10:345-352.
2. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
3. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
4. Binda A.V., Kabbani N., Levenson R. Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS). Biochem Pharmacol 2005, 69:1451-1461.
5. Brunk I., Blex C., Speidel D., Brose N., Ahnert-Hilger G. Ca2+-dependent activator proteins of secretion promote vesicular monoamine uptake. J Biol Chem 2009, 284:1050-1056.
6. Caceda R., Kinkead B., Nemeroff C.B. Involvement of neuropeptide systems in schizophrenia: human studies. Int Rev Neurobiol 2007, 78:327-376.
7. Castensson A., Aberg K., McCarthy S., Saetre P., Andersson B., Jazin E. Serotonin receptor 2C (HTR2C) and schizophrenia: examination of possible medication and genetic influences on expression levels. Am J Med Genet B Neuropsychiatr Genet 2005, 134B:84-89.
8. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50:260-265.
9. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
10. Dunham J.S., Deakin J.F., Miyajima F., Payton A., Toro C.T. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009, 43:1175-1184.
11. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001, 52:79-86.
12. Eran A., Graham K.R., Vatalaro K., McCarthy J., Collins C., Peters H., et al. Comment on "Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients". J Clin Invest 2009, 119:679-680. author reply 680-671.
13. Girgenti, M. J., Nisenbaum, L. K., Bymaster, F., Terwilliger, R., Duman, R. S., Newton, S. S., Antipsychotic-induced gene regulation in multiple brain regions. J Neurochem 113, 175-187.
14. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005, 25:372-383.
15. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009, 66:13-20.
16. Iritani S., Niizato K., Nawa H., Ikeda K., Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:801-807.
17. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
18. Liu Y., Schirra C., Stevens D.R., Matti U., Speidel D., Hof D., et al. CAPS facilitates filling of the rapidly releasable pool of large dense-core vesicles. J Neurosci 2008, 28:5594-5601.
19. Lyon G.J., Abi-Dargham A., Moore H., Lieberman J.A., Javitch J.A., Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull 2011, 37:108-117.
20. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10:1089-1093.
21. Mehler-Wex C., Grunblatt E., Zeiske S., Gille G., Rausch D., Warnke A., et al. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J Neural Transm 2006, 113:1383-1393.
22. Nikolaus S., Antke C., Muller H.W. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res 2009, 204:32-66.
23. M.I.N.I. Mini international neuropsychiatric interview 2005, Seiwa Shoten Publishers, Tokyo. T. Otsubo, H. Miyaoka, K. Kamijima (Eds.).
24. Sadakata T., Itakura M., Kozaki S., Sekine Y., Takahashi M., Furuichi T. Differential distributions of the Ca2+-dependent activator protein for secretion family proteins (CAPS2 and CAPS1) in the mouse brain. J Comp Neurol 2006, 495:735-753.
25. Sadakata T., Mizoguchi A., Sato Y., Katoh-Semba R., Fukuda M., Mikoshiba K., et al. The secretory granule-associated protein CAPS2 regulates neurotrophin release and cell survival. J Neurosci 2004, 24:43-52.
26. Sadakata T., Kakegawa W., Mizoguchi A., Washida M., Katoh-Semba R., Shutoh F., et al. Impaired cerebellar development and function in mice lacking CAPS2, a protein involved in neurotrophin release. J Neurosci 2007, 27:2472-2482.
27. Sadakata T., Washida M., Iwayama Y., Shoji S., Sato Y., Ohkura T., et al. Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. J Clin Invest 2007, 117:931-943.
28. Salio C., Lossi L., Ferrini F., Merighi A. Neuropeptides as synaptic transmitters. Cell Tissue Res 2006, 326:583-598.
29. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
30. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997, 56:131-137.
31. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000, 5:293-300.
32. Thomas E.A. Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol 2006, 34:109-128.
33. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000, 44:151-155.
34. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8:592-610.